Day: July 23, 2025

Oatly Reports Second Quarter 2025 Financial Results

Written by Customer Service on July 23, 2025. Posted in Earnings Releases And Operating Results.

MALMÖ, Sweden, July 23, 2025 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly”, the “Company” or the “Group”), the world’s original and largest oat drink company, today announced financial results for the second quarter ended June 30, 2025. Jean-Christophe Flatin, Oatly’s CEO, commented, “In the first half of the year, we made good progress on our 2025 priorities. We continue to drive cost efficiencies in our supply chain and overhead structure, and our disciplined execution of our growth playbook has seen success in our Europe & International segment, where we are seeing top line momentum. All of these steps are aimed toward our goal of consistently improved profitability. Our updated guidance reflects slower-than-expected top-line progress in our North America segment, as well as a soft macro-environment in our Greater...

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Written by Customer Service on July 23, 2025. Posted in Public Companies.

– XIPERE Now Approved for Use in Multiple Global Markets – – Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® – ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has granted approval for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME). XIPERE is approved for use in the United States, Canada, Australia, and Singapore and under regulatory review in China. About XIPERE® (triamcinolone acetonide injectable suspension) for...

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Written by Customer Service on July 23, 2025. Posted in Public Companies.

WALTHAM, Mass., July 23, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study Group. The SPEAR Study Group was launched earlier this month to focus on the biology and clinical disease or injury associated with persistent presence of spike antigen from SARS-CoV-2 virus or COVID-19 vaccines. Dr. Iwasaki is internationally recognized for her groundbreaking research on viral pathogenesis, human immunobiology, and post-viral chronic conditions, including Long COVID and COVID-19 Post-Vaccination Syndrome (PVS). Dr. Iwasaki is the co-Lead Investigator of the Yale COVID-19 Recovery Study, which investigates how vaccination may alter the immune response in individuals with...

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Written by Customer Service on July 23, 2025. Posted in Public Companies.

FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its DecisionDx-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). DecisionDx-Melanoma is a gene expression profile (GEP) test that provides comprehensive, personalized results to guide risk-aligned management decisions for patients diagnosed with stage I-III cutaneous melanoma. “DecisionDx-Melanoma provides valuable biological insights that help inform clinicians’ post-diagnosis decision making based on a patient’s individual predicted risk of metastasis,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We believe the clinical performance...

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Written by Customer Service on July 23, 2025. Posted in Public Companies.

WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. About NeumoraNeumora...

Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025

Written by Customer Service on July 23, 2025. Posted in Public Companies.

WEST LAFAYETTE, Ind., July 23, 2025 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 third quarter ended June 30, 2025, on Wednesday, August 6, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing:1-800-245-3047 (Domestic) 1-203-518-9765 (International) INOTIV (Conference ID)The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the...

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Written by Customer Service on July 23, 2025. Posted in Public Companies.

REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today issued the following letter to shareholders from Chief Executive Officer Gil Efron, highlighting the Company’s scientific progress, operational execution, and strategic milestones during the first half of 2025. Dear Shareholders, I am pleased to report that the first half of 2025 has been marked by meaningful scientific advancements across all of our core programs, prudent financial management, and continued investor support. Despite a challenging market environment, our team remained focused on delivering value-creating data and positioning Purple Biotech...

Mesa Air Group Files Registration Statement on Form S-4 and S-1 in Connection with Proposed Merger with Republic Airways Holdings Inc.

Written by Customer Service on July 23, 2025. Posted in Mergers And Acquisitions.

PHOENIX, July 23, 2025 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) announced that it filed a registration statement on Form S-4 and S-1 with the U.S. Securities and Exchange Commission (“SEC”) on July 10, 2025 in connection with the Company’s proposed merger (the “Merger”) with Republic Airways Holdings Inc. (“Republic”). The registration statement includes a proxy statement and preliminary prospectus. Once declared effective by the SEC, the final proxy statement/prospectus included in the Form S-4/Form S-1 will be mailed to the Mesa stockholders prior to their vote on the proposed Merger. The registration statement has not yet become effective, and the information contained therein is subject to change. The related securities may not be sold, nor may offers to buy be accepted, prior to...

YieldMax® ETFs Announces Distributions on HOOY, CONY, ULTY, AMDY, YMAG, and Others

Written by Customer Service on July 23, 2025. Posted in Dividend Reports And Estimates.

CHICAGO and MILWAUKEE and NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) — YieldMax® today announced distributions for the YieldMax® Weekly Payers and Group C ETFs listed in the table below.ETF Ticker1 ETF Name Distribution Frequency Distribution per Share Distribution Rate2,4 30-DaySEC Yield3 ROC5 Ex-Date & Record Date Payment DateCHPY YieldMax® Semiconductor Portfolio Option Income ETF Weekly $0.3723 35.54% 0.04% 100.00% 7/24/25 7/25/25GPTY YieldMax® AI & Tech Portfolio Option Income ETF Weekly $0.3219 35.36% 0.00% 100.00% 7/24/25 7/25/25LFGY YieldMax® Crypto Industry & Tech Portfolio Option Income ETF Weekly $0.4876 62.94% 0.00% 100.00% 7/24/25 7/25/25QDTY YieldMax® Nasdaq 100 0DTE Covered Call ETF Weekly $0.1944 22.64% 0.00% 86.12% 7/24/25 7/25/25RDTY YieldMax® R2000 0DTE Covered Call ETF Weekly $0.3901 44.01% 1.65% 100.00% 7/24/25 7/25/25SDTY YieldMax®...

MAG Announces Second Quarter 2025 Production From Juanicipio

Written by Customer Service on July 23, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) — MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG” or “MAG Silver”) reports production from Juanicipio (56% / 44% Fresnillo plc (“Fresnillo”) and MAG, respectively) for the second quarter (“Q2”) ended June 30, 2025. All results below on a 100% basis unless otherwise stated. Safety incident: It is with deep sorrow that we confirm the tragic loss of a valued colleague in a fatal incident at Juanicipio in July. Our hearts go out to his family, friends, and teammates during this incredibly difficult time. Together with Fresnillo, we are offering our full support to those affected, including counseling services and other resources, and remain in close contact with the family to provide ongoing assistance. The safety and well-being of our people is our highest priority. Every...

Day: July 23, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals